# Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC

> **NCT03673137** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 120 (actual)

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma

## Interventions

- **DEVICE:** Irreversible electroporation
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03673137
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673137, "Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03673137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*